Free Daily Podcast Summary
Oncology Brothers: Practice-Changing Cancer Discussions: Daily Summaries Delivered
by Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 2 days ago20 min
Management of NSCLC with Common EGFR Mutations: Dr. Ben Levy
We dived into this evolving landscape of treatment options for common sensitizing EGFR mutations in non-small cell lung cancer (NSCLC). In this episode, we were joined by Dr. Benjamin Levy, a thoracic medical oncologist at Johns Hopkins, to discuss the latest advances in frontline therapies, including single-agent osimertinib, osimertinib plus chemotherapy, and the promising combination of amivantamab and lazertinib. Key topics covered include: The prevalence of EGFR mutations in metastatic non-small cell adenocarcinoma The shift from single-agent osimertinib to combination therapies and the implications for patient care Factors influencing treatment decisions, including patient preference, side effect profiles, and co-mutations The importance of shared decision-making in oncology Insights into managing central nervous system (CNS) involvement and the nuances of treatment sequencing at progression Whether you're a healthcare professional or simply interested in the latest in cancer treatment, this episode provides valuable insights into the complexities of managing EGFR-mutated lung cancer. Don't miss out on this informative discussion! Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Stay tuned for our next episode featuring Susan Scott, MD, where we will explore uncommon EGFR mutations. #EGFRmNSCLC, #Osimertinib, #Amivantamab, #Lazertinib, #OncologyBrothers
- 4 days ago27 min
ESMO 2026 Lung Cancer Highlights: DeLLphi-305, SAFFRON, KRASCENDO-1, PERSEE
Welcome back to the Oncology Brothers podcast! In this episode, we discussed practice changing/informing studies from the ESMO 2026 conference, focusing on the latest advancements in lung cancer treatment. Join us as we welcomed Dr. Hossein Borghaei, a thoracic medical oncologist from the Fox Chase Cancer Center, to discuss 4 key studies that could change clinical practice: DeLLphi-305: how the combination of durvalumab and tarlatamab after chemotherapy has led to a remarkable increase in median overall survival (OS) for patients with extensive-stage small cell lung cancer (ES-SCLC) SAFFRON: Learn about the efficacy of osimertinib combined with savolitinib for EGFR-mutated lung cancer patients with MET overexpression, showing significant improvements in progression-free survival (PFS) and OS compared with traditional chemotherapy KRASCENDO-1: We explored the new KRAS G12C inhibitor, divarasib, and its promising results against established treatments like sotorasib and adagrasib, highlighting its favorable toxicity profile PERSEE: Talked about the ongoing debate on whether chemotherapy should be added to immunotherapy for patients with high PD-L1 scores, as new data suggests potential benefits Tune in for an insightful discussion that aims to keep you informed on the latest in oncology and improve patient care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #LungCancer, #ESMO2026, #NSCLC, #SCLC, #OncologyBrothers
- 5 days ago23 min
ESMO 2026 GI Cancer Highlights: HERIZON-GEA-01, CLARITY-GASTRIC01, AZUR1, CHECKMATE 8HW, HARMONi-GI1
Welcome to the Oncology Brothers podcast! In this episode, we dived into the highlights from the ESMO 2026 conference, focusing on key studies in gastrointestinal (GI) malignancies. Join us as we discussed: HERIZON-GEA-01: Zanidatamab, a biparatopic HER2 antibody for HER2-positive upper GI adenocarcinoma, showcasing updated overall survival (OS) data and its implications for treatment CLARITY-Gastric 01: The first antibody-drug conjugate (ADC) targeting CLDN18.2, demonstrating significant improvements in OS for patients in the second- and third-line settings AZUR-1: Dostarlimab’s recent approval for MSI-high rectal cancer, highlighting its potential to allow patients to avoid radiation and surgery CheckMate 8HW: Insights into the superiority of dual checkpoint inhibition over single-agent immunotherapy for MSI-high metastatic colorectal cancer HARMONi-GI1: A look at ivonescimab combined with chemotherapy in biliary tract cancer, showing promising results despite being a China-only study Tune in for expert insights from GI medical oncologists Drs. Eric Van Cutsem and Manish Shah, as they share their thoughts on these pivotal studies and their impact on clinical practice. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers podcast! #GIOncology, #ESMO2026, #UpperGI, #Colorectal, #OncologyBrothers
- 1 weeks ago22 min
ESMO 2026 Head & Neck Melanoma Highlights OrigAMI-4, INTerpath-001, STARBOARD
In this discussion we dived into the latest breakthroughs in head and neck cancer and melanoma from ESMO 2026. In this episode, we welcomed Dr. Ari Rosenberg from the University of Chicago, to discuss promising data on amivantamab for HPV-negative head and neck cancer, including its efficacy in frontline settings and important considerations for managing side effects. We also had the opportunity to talk to Dr. Sapna Patel from the University of Colorado, who shared insights on the INTerpath-001 study, exploring the role of personalized mRNA vaccines in the adjuvant setting for melanoma. Additionally, we discussed the STARBOARD trial, which investigated the triplet therapy of pembrolizumab, encorafenib, and binimetinib for BRAF V600E/K-positive melanoma patients. Tune in to hear our thoughts on how these findings may change clinical practice and the future of treatment options in oncology. Key Points Amivantamab shows promising efficacy in HPV-negative head and neck cancer, particularly in the frontline setting, with a manageable toxicity profile that requires proactive side effect management. Personalized mRNA vaccines in the adjuvant setting for melanoma represent a novel approach, with the INTerpath-001 study comparing this strategy against current standards of care. The STARBOARD trial evaluates triplet therapy with pembrolizumab, encorafenib, and binimetinib in BRAF V600E/K-positive melanoma, with the potential to change clinical practice. Logistical challenges, including vaccine manufacturing timelines and treatment coordination, remain important considerations for implementing these emerging therapies. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #HeadAndNeckCancer, #Melanoma, #mRNAVaccine, #OncologyBrothers
- 1 weeks ago18 min
RCC Management in Localized & Metastatic Disease with Dr. Monty Pal - Rapid-Fire Rounds
Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sumanta "Monty" Pal, MD, a GU medical oncologist from the City of Hope, for a rapid-fire round discussing key questions from the oncology community about renal cell carcinoma (RCC). Join us as we dived into topics including: The standard of care for early-stage RCC and the role of adjuvant therapies like pembrolizumab with and without belzutifan Treatment strategies for oligometastatic disease and the use of radiation Insights on the use of circulating tumor DNA (ctDNA) in adjuvant settings and the implications of treatment breaks for patients on immuno-oncology (IO)–tyrosine kinase inhibitor (TKI) regimens The evolving landscape of metastatic RCC, including the comparison of IO-IO versus IO-TKI combinations and the importance of patient-centered decision-making The challenges and considerations in treating non–clear cell RCC, including the latest data on treatment options Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes! #RCC, #KidneyCancer, #AdjuvantTherapy, #IO-TKI, #OncologyBrothers
- 1 weeks ago21 min
ESMO 2026 GU Highlights VOLGA, DASL-HiCAP, PROTEUS, KEYNOTE-564, LITESPARK-011
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Drs. Shilpa Gupta and Ashish Kamat, to discuss the latest updates from ESMO 2026 in Madrid. With nearly 40,000 attendees and thousands of abstracts presented, we focus on the most impactful findings in genitourinary (GU) oncology. Episode Highlights: Muscle-Invasive Bladder Cancer (MIBC): A deep dive into the VOLGA trial, exploring the efficacy of neoadjuvant therapy with durvalumab and enfortumab vedotin (EV) in MIBC. We discussed the implications of reduced toxicity and potential changes to standard care. Non-Muscle-Invasive Bladder Cancer (NMIBC): Insights from the POTOMAC update and the role of durvalumab in high-risk, BCG-naive patients. Prostate Cancer: An overview of the DASL-HiCaP and PROTEUS studies, highlighting the use of androgen receptor pathway inhibitors (ARPIs) in earlier lines of treatment and their impact on metastasis-free survival (MFS). Renal Cell Carcinoma (RCC): Updates on KEYNOTE-564 and the LITESPARK studies, focusing on adjuvant therapies and the balance between efficacy and side effects. Join us as we cut through the noise and focus on what is practice-changing in the field of oncology. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to subscribe for more insights and updates from the world of cancer research! #ESMO2026, #GUOncology, #BladderCancer, #ProstateCancer, #KidneyCancer, #OncologyBrothers
- 3 weeks ago25 min
Multiple Myeloma CAR-T Management - Partners in Practice
In this episode of the Oncology Brothers podcast, we dived deep into the complexities of second-line treatment options for multiple myeloma, with a special focus on CAR T-cell therapy. Joined by experts Dr. Rafael Fonseca, a multiple myeloma specialist from the Mayo Clinic; Dr. Beth Faiman, a nurse practitioner specializing in myeloma; and Ms. Carrie Bellerive, a clinical nurse coordinator at Memorial Sloan Kettering Cancer Center, the discussion covers: The eligibility criteria for CAR T-cell therapy and the data supporting its effectiveness Insights from recent clinical trials, including CARTITUDE-1 and CARTITUDE-2, highlighting long-term outcomes and potential for cure The importance of patient preparation and shared decision-making in treatment planning The role of bridging therapy and the significance of managing disease burden prior to CAR T-cell infusion An overview of acute and chronic side effects associated with CAR T-cell therapy, including cytokine release syndrome (CRS) and neurotoxicity The critical coordination efforts behind the scenes to ensure seamless patient care Join us as we explore how collaboration among healthcare professionals can enhance patient outcomes in the evolving landscape of multiple myeloma treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! #MultipleMyeloma, #CARTtherapy, #BridgingTherapy, #HoldingTherapy, #OncologyBrothers
- 3 weeks ago22 min
CAR-T Cell Therapy in Multiple Myeloma & Lymphoma - Clinical Foundations
Welcome to the Oncology Brothers podcast! In this episode, we dived into the world of CAR T-cell therapy, featuring insights from hematology experts Drs. Luciano Costa and Shernan Holtan. Join us as we explore: The basics of CAR T-cell therapy and the patient journey from referral to infusion The approved indications for CAR T-cell therapy in multiple myeloma and lymphoma, including the differences between idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) The importance of holding and bridging therapies to optimize patient outcomes The evolving landscape of side effects associated with CAR T-cell therapy, including acute and chronic effects Strategies for community oncologists to better manage patient care and improve access to CAR T-cell therapies With the potential for curative outcomes in myeloma and lymphoma, understanding these therapies is crucial for both patients and healthcare providers. Tune in for an informative discussion that aims to bridge the gap between community oncology and specialized care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest advancements in cancer treatment! #CARTtherapy, #MultipleMyeloma, #Lymphoma, #BridgingTherapy, #OncologyBrothers
Get Oncology Brothers: Practice-Changing Cancer Discussions summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
INTERLUDE: Cancer Stories with Dr. Teplinsky
Eleonora Teplinsky
Out of the Gray (Gy) - Standard Imaging
Conversations with experts in radiation oncology exploring advancements in technology, research, and clinical practice.
The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.
Core IM | Internal Medicine Podcast
A podcast exploring internal medicine through clinical reasoning, management decisions, and practical teaching points.
Thrive Through and Beyond Cancer
Season Johnson
Frankly Speaking About Family Medicine
Discusses current topics and developments in primary care and family medicine.
The Antisocial Doctors Podcast
Sonia Singh MD & Rebecca Berens MD
Red Pill Your Healthcast
Two healthcare providers discuss overlooked health issues and empower listeners to make informed decisions for their families.
ICU Ed and Todd-Cast
Eddie and Todd
The Peter Attia Drive
Conversations with experts on health, longevity, performance, and critical thinking led by physician Peter Attia.
The Dr. Hyman Show
Explores root causes of chronic disease and promotes functional medicine, nutrition, and preventive health through expert discussions.
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
Answers in CME
About Oncology Brothers: Practice-Changing Cancer Discussions
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Oncology Brothers: Practice-Changing Cancer Discussions in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Oncology Brothers: Practice-Changing Cancer Discussions daily summary?
It's a free AI-powered email that summarizes new episodes of Oncology Brothers: Practice-Changing Cancer Discussions as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Oncology Brothers: Practice-Changing Cancer Discussions podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Oncology Brothers: Practice-Changing Cancer Discussions product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Oncology Brothers.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does Oncology Brothers: Practice-Changing Cancer Discussions release new episodes?
Oncology Brothers: Practice-Changing Cancer Discussions publishes 2x weekly. Our AI generates a summary within hours of each new episode.
What topics does Oncology Brothers: Practice-Changing Cancer Discussions cover?
Oncology Brothers: Practice-Changing Cancer Discussions covers topics including Medicine, Fitness, Health & Fitness. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Oncology Brothers: Practice-Changing Cancer Discussions summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.